公开(公告)号：US20200231623A1

公开(公告)日：2020-07-23

申请号：US16648123

申请日：2018-09-17

Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

Inventor： Fajun NAN ,  Xin XIE ,  Chenlu ZHANG ,  Shimeng GUO ,  Yangming ZHANG ,  Siwei WANG

IPC: C07J63/00

Abstract: Disclosed are a pentacyclic triterpene compound as shown in general formula (I) and a preparation method therefor. The compound has an effective antagonistic effect on FXR receptors.

公开(公告)号：US20180064696A1

公开(公告)日：2018-03-08

申请号：US15556932

申请日：2016-03-03

Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

Inventor： Fajun NAN ,  Boliang LI ,  Yang ZHAN ,  Xiaowei ZHANG ,  Ying XIONG ,  Xichan HU ,  Yangming ZHANG

IPC: A61K31/4433 ,  A61K31/352 ,  C07D493/04

CPC classification number: A61K31/4433 ,  A61K31/352 ,  C07B37/04 ,  C07B49/00 ,  C07D493/04

Abstract: The present invention relates to a series of analogues of natural product Pyripyropene A represented by general formula I and a preparation method and use thereof. More particularly, the present invention relates to analogues of the natural product Pyripyropene A, a preparation method and use thereof as the acyl-CoA:cholesterol acyltransferase 2 (ACAT2) inhibitors for the treatment of cardiovascular diseases such as atherosclerosis and the like.

公开(公告)号：US20190211005A1

公开(公告)日：2019-07-11

申请号：US16329336

申请日：2017-08-24

Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

Inventor： Fajun NAN ,  Jia LI ,  Jian DING ,  Meiyu GENG ,  Yangming ZHANG ,  Yi CHEN ,  Yubo ZHOU ,  Chaojun GONG ,  Mingbo SU ,  Anhui GAO

IPC: C07D417/04 ,  A61P35/02

Abstract: The invention describes an aryl-2,2′-tandem bisthiazole compound and a preparation method and the use thereof. In particular, disclosed in the present invention are an aryl-2,2′-tandem bisthiazole compound with the structure as shown in general formula I and the preparation method thereof and use thereof as a histone deacetylase inhibitor in the preparation of antitumor drugs.

公开(公告)号：US20240351966A1

公开(公告)日：2024-10-24

申请号：US18290268

申请日：2022-05-11

Applicant: Shanghai Institute of Materia Medica, Chinese Academy of Sciences

Inventor： Fajun NAN ,  Jingya LI ,  Zheng ZHANG ,  Yanan DUAN ,  Yangming ZHANG ,  Dandan CHEN ,  Chengqiu DAI

IPC: C07C39/19 ,  A61K31/05 ,  A61K31/09 ,  A61K31/136 ,  A61K31/145 ,  A61K31/167 ,  A61K31/341 ,  A61K31/381 ,  A61K31/40 ,  A61K31/44 ,  A61K31/505 ,  C07C43/215 ,  C07C43/23 ,  C07C215/76 ,  C07C233/88 ,  C07D213/69 ,  C07D213/74 ,  C07D239/10 ,  C07D307/36 ,  C07D333/06 ,  C07D333/34

CPC classification number: C07C39/19 ,  A61K31/05 ,  A61K31/09 ,  A61K31/136 ,  A61K31/145 ,  A61K31/167 ,  A61K31/341 ,  A61K31/381 ,  A61K31/40 ,  A61K31/44 ,  A61K31/505 ,  C07C43/215 ,  C07C43/23 ,  C07C215/76 ,  C07C233/88 ,  C07D213/69 ,  C07D213/74 ,  C07D239/10 ,  C07D307/36 ,  C07D333/06 ,  C07D333/34

Abstract: Provided are a class of alkylphenol compounds and a preparation method therefor. Specifically provided are a new alkyl polyphenol compound as represented by chemical formula I, and a preparation method therefor and the use thereof in the treatment of metabolic syndrome.

公开(公告)号：US20170081301A1

公开(公告)日：2017-03-23

申请号：US15306971

申请日：2015-04-22

Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

Inventor： Fajun NAN ,  Min LI ,  Zhaobing GAO ,  Yangming ZHANG ,  Haining HU ,  Haiyan XU ,  Huanan LIU ,  Xiaoping PI

IPC: C07D307/24 ,  C07C237/48 ,  C07C275/64 ,  C07C235/16 ,  C07C271/28 ,  C07C333/08

CPC classification number: C07D307/24 ,  A61K31/167 ,  A61K31/17 ,  A61K31/27 ,  A61K31/277 ,  A61K31/341 ,  C07C231/02 ,  C07C233/62 ,  C07C235/16 ,  C07C235/74 ,  C07C237/04 ,  C07C237/22 ,  C07C237/48 ,  C07C269/04 ,  C07C269/06 ,  C07C271/28 ,  C07C273/18 ,  C07C275/64 ,  C07C333/08 ,  C07C2601/02 ,  C07C2601/14

Abstract: The present invention provides a compound represented by general formula I or a pharmaceutical acceptable salt thereof, the preparation method therefor and the use thereof in preparing a medicine for treating a neurological disease, such as epilepsy, convulsion, neuropathic pain, acute ischemic stroke, and a neurodegenerative disease. The compound according to present invention has a better absorption in brain tissue when compared with RTG. In addition, the compound provided by present invention has not only a greatly enhanced efficacy, but also a neurotoxicity greatly lower than that of RTG, and thus possesses a wider safety window.

公开(公告)号：US20170044119A1

公开(公告)日：2017-02-16

申请号：US15301763

申请日：2015-03-27

Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

Inventor： Fajun NAN ,  Jia LI ,  Xin XIE ,  Chaojun GONG ,  Yubo ZHOU ,  Hui CHAI ,  Yangming ZHANG ,  Mingbo SU

IPC: C07D277/56 ,  C07D417/14 ,  C07D277/60

CPC classification number: C07D277/56 ,  C07D277/60 ,  C07D277/66 ,  C07D417/04 ,  C07D417/14

Abstract: The present invention relates to a thiazole-based compound, a preparation method therefor, and a use thereof. More specifically, the present invention relates to a 2,2′-bis-thiazole-based compound, a preparation method therefor, and a use of 2,2′-bis-thiazole-based compound a histone deacetylase inhibitor in the preparation of an antitumor medicament, a medicament for treating autoimmune diseases, a medicament for treating type II diabetes mellitus and complication thereof, or a medicament for treating neurodegenerative diseases.

Abstract translation: 本发明涉及一种噻唑类化合物及其制备方法及其应用。 更具体地说，本发明涉及2,2'-双噻唑类化合物及其制备方法，以及使用组氨酸脱乙酰酶抑制剂的2,2'-双噻唑类化合物制备 抗肿瘤药物，用于治疗自身免疫性疾病的药物，用于治疗II型糖尿病的药物及其并发症，或用于治疗神经变性疾病的药物。